Acamprosate calc DR 333 MG tab 180S
Ended Awarded Last action
- Contract number
- SPE2DR26F3G4H
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $3,062
Award facts
- Contract value 100% obligated
- $3,062.23 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
On January 30, 2026, the Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp (UEI: KABZK8W6PQT3) for Acamprosate Calcium 333 mg tablets in a quantity of 180 units. This competitively awarded, firm fixed-price delivery order has a ceiling value of $3,062.23 and an ultimate completion date of February 2, 2026. The product will be performed at the vendor's facility in Conshohocken, Pennsylvania. This delivery order was issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999.00 through December 31, 2031. This prime IDC serves as a comprehensive global pharmaceutical support vehicle enabling the delivery of a wide range of pharmaceutical products, medical supplies, specialty medications, brand-name and generic drugs, vaccines, and related medical commodities to support military healthcare programs worldwide, including the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Acamprosate calcium is an FDA-approved medication primarily used in the treatment of alcohol use disorder to maintain abstinence in patients who have already undergone detoxification. The issuance of this delivery order reflects the federal government's ongoing pharmaceutical supply needs within its military and veteran healthcare networks. No set-aside designation was applied to this award, indicating the contract was awarded through full and open competition. AmerisourceBergen Drug Corp, as the prime contractor and subsidiary of Cencora, Inc., continues to serve as a critical vendor for federal medical procurement, demonstrating its capability to fulfill government requirements for specialized pharmaceutical commodities across multiple therapeutic domains.
Quick answers
Who was awarded contract SPE2DR26F3G4H?
SPE2DR26F3G4H was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26F3G4H worth?
The government has obligated $3,062 on SPE2DR26F3G4H.
Is contract SPE2DR26F3G4H an order under another contract?
Yes. SPE2DR26F3G4H is a delivery order under SPE2DR25D3001, an indefinite delivery contract.
Was contract SPE2DR26F3G4H competed?
The extent of competition for SPE2DR26F3G4H was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award